Received On: 11/05/2012
Accepted On: 16/05/2012
Patel, M.A., Shah, J.A., Patel, B.A., Patel, K.N., Patel, P.A.
Piroxicam is a non steroidal anti-inflammatory drug with analgesic properties. The purpose of this study was to develop a taste masked orally disintegrating tablet of poorly soluble Piroxicam by direct compression technique with β-cyclodextrin (ß-CD) complexes using various superdisintegrants like sodium starch glycolate, crospovidone XL and croscarmellose sodium. Complex was characterized using infrared spectroscopy, differential scanning calorimetry, % drug release study, gustatory evaluation for taste masking. A 32 full factorial design was applied to systematically optimize the drug disintegration time. The concentration of Crospovidone (X1) and concentration of Croscarmellose (X2) were selected as independent variables. The Disintegration time (Y1) and Wetting time (Y2) were selected as dependent variables. The prepared tablets were evaluated for hardness, friability, disintegration time, wetting time and In-vitro drug release. FT-IR studies and physical compatibility study were conducted for drug, and drug excipient mixture for interactions if any. The different formulations showed disintegration time between 12 to 58 sec. The results indicated that concentration of Crospovidone (X1) and concentration of Croscarmellose (X2) significantly affected the Disintegration time (Y1) and Wetting time (Y2). Regression analysis and numerical optimization were performed to identify the best formulation. Formulation F10 prepared with croscarmellose (4.23%) & crospovidone (6.74%) was found to be the best formulation with disintegration time 16 sec, wetting time 21 sec and % drug release in 10 min 94.23%.
Piroxicam, Orally disintegrating tablet, ß-cyclodextrin, Crospovidone, Croscarmellose, Disintegration time, Wetting time
Cite This Article
Patel, M.A., Shah, J.A., Patel, B.A., Patel, K.N., Patel, P.A. (2012). Formulation, Optimization and Evaluation of Orally Disintegrating Tablet of Non-Steroidal Anti-inflammatory Drug, International Journal for Pharmaceutical Research Scholars (IJPRS), 1(2), 190-205.